All In Biotech

Drug Trial Radar · NCT04890587

A Phase I Study of AL8326 in Advanced Solid Tumor

A Dose Escalation Tolerance and Pharmacokinetics Study of AL8326 in Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: May 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

40

Planned (sponsor's estimate)

Start

Aug 17, 2017

Primary completion

Dec 2023

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
May 18, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Main purpose Objective to study the tolerance and safety of single and multiple administration of repeated 28-day cycles of AL8326 in patients with advanced solid tumor, observe the dose limiting toxicity (DLT) and maximum tolerated dose (MTD). 2. Secondary purpose 1) Preliminary analysis of the pharmacokinetic characteristics and efficacy of repeated 28-day cycles of AL8326 tablets in patients with advanced solid tumors; 2) According to the results of phase I tolerance test and pharmacokinetics, appropriate dosage and regimen were recommended for phase II clinical trial;

Conditions

  • Advanced Solid Tumors

Interventions

  • AL8326 tabletsDrug

    Tablet:10mg/tablet; administered orally once daily in part 1 and part 2, administered orally twice daily for continuous 28-Day cycles in part 3.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: cycle1 (each cycle is 28-days)
  2. Maximum tolerated dose (MTD)Time frame: cycle1 (each cycle is 28-days)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.